Search research articles
Contact Us
Filters
Showing results (101-110 of 130) with videos related to
Page
of 13
Sort By:
The New England Journal of Medicine
|
December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2023
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
Dae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, et al.
Cell Reports. Medicine
|
May 14, 2024
IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy
Kun-Joo Lee, Donghoon Choi, Nara Tae, et al.
Cancer Research and Treatment
|
August 5, 2016
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, et al.
Cancer Research and Treatment
|
November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Cancer Communications (London, England)
|
May 30, 2019
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Ji-Yeon Kim, Seri Park, Seock-Ah Im, et al.
Genome Biology
|
April 14, 2026
Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer
Dong Ki Lee, Min Hwan Kim, Yumi Hwang, et al.
Cancer Research and Treatment
|
April 13, 2023
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, et al.
Future Oncology (London, England)
|
June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
Page
of 13
Search research articles
Search
Showing results (101-110 of 130) with videos related to
Sort By:
Page
of 13
The New England Journal of Medicine
|
December 12, 2019
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi, Cristina Saura, Toshinari Yamashita, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 17, 2023
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial
Dae-Won Lee, Kyung Hae Jung, Kyung-Hun Lee, et al.
Cell Reports. Medicine
|
May 14, 2024
IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy
Kun-Joo Lee, Donghoon Choi, Nara Tae, et al.
Cancer Research and Treatment
|
August 5, 2016
Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
Yeon Hee Park, Tae Yong Kim, Young-Hyuck Im, et al.
Cancer Research and Treatment
|
November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
Komal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Cancer Communications (London, England)
|
May 30, 2019
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Ji-Yeon Kim, Seri Park, Seock-Ah Im, et al.
Genome Biology
|
April 14, 2026
Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer
Dong Ki Lee, Min Hwan Kim, Yumi Hwang, et al.
Cancer Research and Treatment
|
April 13, 2023
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
Young-Woong Won, Jin-Hyoung Kang, Jung Hye Kwon, et al.
Future Oncology (London, England)
|
June 30, 2023
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer
Aditya Bardia, Komal Jhaveri, Kevin Kalinsky, et al.
Page
of 13